AI Insights
Artificial Intelligence (AI) technology, combined with big data, hold the potential to solve many key clinical trial challenges.
Big Data and AI technologies are complimentary as AI can help to synthesize and analyse ever-expanding data.
AI-powered capabilities, including data integration and interpretation, pattern recognition and evolutionary modelling, are essential to gather, normalise, analyse and harness the growing masses of data that fuel modern therapy development. Indeed, AI and advanced analytics were viewed as the digital technology with the most potential to improve clinical R&D productivity in our Digital Disruption in Biopharma industry survey.
AI has many potential applications in clinical trials both near- and long-term. AI technologies make possible innovations that are fundamental for transforming clinical trials, such as seamlessly combining phase I and II of clinical trials, developing novel patient-centered endpoints, and collecting and analysing Real World Data.
Decoding AI in software as a medical device (SaMD)
This whitepaper provides a starting point for medical device researchers considering use of AI in SaMDs. Understanding the FDA regulatory requirements and guidance on submissions can enable medical device researchers to plan their route to market and avoid potential obstacles on the way.
Advancing rare disease research through AI innovation and patient trust
How close are we to unlocking AI’s full potential in rare disease trials? Discover how it’s transforming discovery, design, and patient engagement in this ACRO podcast.
Integrating AI Insights into clinical research
AI is transforming clinical research – making drug development faster, more efficient, and more precise. ICON’s latest whitepaper explores how AI is already being integrated into clinical operations, featuring insights from the 2024 Citeline Survey and global research from Tufts CSDD and DIA.
Applying AI to manage the risks and costs of postmarketing requirements
Our award-winning Cassandra AI system harnesses real world data on drugs and data obtained from the US FDA and EMA postmarketing requirements databases to accurately forecast whether postmarketing studies will be necessary.
Advancements in AI for site selection
Learn how ICON is using human-enabled AI to efficiently integrate, interrogate and interpret large datasets from diverse sources and gain valuable insights for site selection in both expected and unexpected ways.
The impact of artificial intelligence on outcomes based contracting
In the United States outcomes-based contracting (OBC) has long been proposed as a measure to reward innovation, based on actual performance of treatments and interventions in patient populations. However, the perceived and actual challenges in implementation have prevented many innovative contracts from leaving the drafting table.
Recently, the potential use of artificial intelligence (AI) to predict suitable outcomes for patients to mitigate potential challenges has been discussed. Read our whitepaper for insights on the latest trends and challenges.
How AI and other digital technologies will transform R&D productivity enough to restore ROI
In our recent white paper 'Digital Disruption in Biopharma' over 83% of survey respondents were piloting, or maturely using, AI technologies.
There were significant gains in reported benefits from use of AI compared to our digital original survey in 2019. 'Identifying biomarkers for predicting responsive patient populations' and 'Creating more predictive models to accelerate clinical trials' were the top two anticipated benefits of AI technologies
AI webinars
Artificial Intelligence at ICON
Artificial intelligence (AI) is a general term for software that mimics human cognition or perception. Rapid progress in AI is transforming many industries with considerable impact, including clinical trials.
Watch the recording.
Advancements in AI for optimal clinical trial site identification: Turning Big Data into actionable intel
Despite advancing technologies, clinical trials still struggle to meet patient enrolment goals. Slow enrolment directly impacts schedule and budget, with each day of delay carrying cripplingly high costs.
Watch the recording.
The future of pharmacovigilance: Exploring automation and AI in literature surveillance
In this webinar, industry experts explore the future of Pharmacovigilance and offer key insights on the critical role of literature surveillance in the pharmaceutical and biotech sectors, and how automation is revolutionising the process.
Watch the recording.
AI at ICON
Our portfolio of award-winning AI solutions are designed to accelerate trial timelines, improve data accuracy, optimise resource management, and ensure compliance — all while maintaining the highest ethical standards.
AI and clinical trials blogs and media contributions
-
Media article: When your CRO’s AI platform upgrades, who pays for the change management?
This article examines the operations and cost considerations of ICON’s AI platform evolution, following it’s partnership with Microsoft to scale the Orbis platform across clinical trials.
-
Media article: ICON names Microsoft tech partner as Q1 results grow analyst confidence
This article reports on ICON naming Microsoft as a technology partner to scale its Orbis AI platform, while highlighting growing analyst confidence driven by improving performance and demand.
-
Media article: ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery
This podcast discusses ICON’s selection of Microsoft as a preferred technology partner to scale its agentic AI platform across the clinical trial lifecycle.
-
Media article: ICON selects Microsoft to power AI-enabled clinical development
This article reports on ICON’s selection of Microsoft as a preferred technology Partner, bringing Microsoft 365 Copilot, Azure, and AI infrastructure to scale its Orbis Platform and enable AI-driven clinical development.
-
Media article: ICON selects Microsoft as preferred technology partner to scale agentic AI platform across clinical trial lifecycle
This article reports on an enterprise-wide partnership that brings Microsoft 365 Copilot, Azure, and Fabric infrastructure to ICON's Orbis platform, supporting AI deployment across study design, site operations, and regulatory workflows.
-
Media article: From automation to autonomy: How agentic AI is redefining biopharma's digital workforce
This article will explore the emerging architecture of agentic AI in biopharma: what distinguishes agents from traditional rules-based automation, how multi-agent systems orchestrate work across fragmented environments, and why strong governance and upskilled teams are essential to preventing “black-box” operational drift.
-
Blog: Real-time clinical trials: a pivotal shift and a global question
While the FDA’s direction is gaining attention, a more important question for sponsors is emerging: how will this approach translate in a global regulatory landscape?
-
Media article: Reimagining vaccine development with AI
Explore how AI is accelerating vaccine development, improving speed, precision, and global readiness.
The power of AI to transform clinical trials
The AI transformation of clinical trials starts with protocol development, reducing or replacing outcome assessments that may be more responsive to change than traditional methods and utilising remote connected technologies that reduce the need for patients to travel long distances for sites visits.
Data-driven protocols and strategies powered by advanced AI algorithms processing data collected from mobile sensors and apps, electronic medical and administrative records, and other sources have the potential to reduce trial costs. They achieve this by improving data quality, increasing patient compliance & retention, and identifying treatment efficacy more efficiently and reliably than ever before.
Latest on AI, Predictive Informatics, Wearables
If you would like to receive our Digital Disruption email updates, including the latest on mHealth and wearables, as well as AI and predictive informatics, click here to go to our preference centre.
Leveraging voice-assistant technology in clinical trials
In addition to the rise in mobile and wearable solutions, AI powered digital voice assistants are becoming ubiquitous, with every smartphone today now shipping with either Siri or Google Assistant, while smart speakers like the Amazon Echo with Alexa and Google Home are becoming the hubs for smart homes.
Voice assistant technologies provide an opportunity to create a different level of engagement and interaction with patients in comparison to regular apps and web pages. ICON have developed a proof-of-concept application operating on the Amazon Echo platform that leverages a Voice Assistant to deliver a patient-reported outcome instrument and collect patient responses.
